Relief Therapeutics Holding SA
SIX:RLF
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.06
4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CH |
|
Relief Therapeutics Holding SA
SIX:RLF
|
437m CHF |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
377.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
156.2B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.6B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
46.7B USD |
Loading...
|
Market Distribution
| Min | -62 472.2% |
| 30th Percentile | 3.5% |
| Median | 10.3% |
| 70th Percentile | 16.5% |
| Max | 91.2% |
Other Profitability Ratios
Relief Therapeutics Holding SA
Glance View
RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve and currently employs 55 full-time employees. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Relief Therapeutics Holding SA is -484.4%, which is below its 3-year median of -294.5%.
Over the last 3 years, Relief Therapeutics Holding SA’s Operating Margin has increased from -586.3% to -484.4%. During this period, it reached a low of -586.3% on May 30, 2022 and a high of -88.5% on Dec 31, 2024.